Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Rises By 796.7%

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 1,029,832 shares, an increase of 796.7% from the July 30th total of 114,842 shares. Based on an average trading volume of 420,053 shares, the short-interest ratio is presently 2.5 days. Approximately 0.0% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on FSNUY shares. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

OTCMKTS:FSNUY traded down $0.08 during trading hours on Tuesday, reaching $13.39. 58,204 shares of the company’s stock were exchanged, compared to its average volume of 155,321. The company has a market capitalization of $30.17 billion, a P/E ratio of 16.95 and a beta of 0.61. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $33.93. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. The business’s 50-day simple moving average is $12.53 and its two-hundred day simple moving average is $12.70.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.33%. The company had revenue of $6.91 billion for the quarter, compared to analysts’ expectations of $6.65 billion. Sell-side analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.